HC Wainwright reaffirmed their buy rating on shares of enGene (NASDAQ:ENGN – Free Report) in a report issued on Monday,Benzinga reports. The brokerage currently has a $25.00 price target on the stock. HC Wainwright also issued estimates for enGene’s FY2030 earnings at $0.70 EPS. Other equities analysts have also recently issued research reports about the […]

HC Wainwright restated their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO – Free Report) in a research report report published on Tuesday,Benzinga reports. HC Wainwright currently has a $20.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Abeona Therapeutics’ Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at $1.23 […]

HC Wainwright reaffirmed their buy rating on shares of Foghorn Therapeutics (NASDAQ:FHTX – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a $13.00 target price on the stock. Other equities research analysts have also issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating […]

HC Wainwright restated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) in a research report sent to investors on Tuesday morning, Marketbeat Ratings reports. They currently have a $60.00 price target on the biotechnology company’s stock. Several other research firms have also issued reports on CAPR. Roth Mkm boosted their target […]

HC Wainwright reiterated their neutral rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN – Free Report) in a research note published on Tuesday morning, Marketbeat reports. They currently have a $21.50 price objective on the stock, down from their prior price objective of $22.00. Several other analysts also recently issued reports on the company. Oppenheimer […]